



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## NVS-PAK1-1

Cat. No.:	HY-100519
CAS No.:	1783816-74-9
Molecular Formula:	C <sub>23</sub> H <sub>25</sub> ClF <sub>3</sub> N <sub>5</sub> O
Molecular Weight:	479.93
Target:	PAK
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton
Storage:	<div> Powder -20°C 3 years </div> <div> 4°C 2 years </div> <div> In solvent -80°C 1 year </div> <div> -20°C 6 months </div>



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (208.36 mM; Need ultrasonic)				
	Preparing Stock Solutions	<div>Solvent Concentration</div> <div>Mass</div>	1 mg	5 mg	10 mg
		1 mM	2.0836 mL	10.4182 mL	20.8364 mL
		5 mM	0.4167 mL	2.0836 mL	4.1673 mL
		10 mM	0.2084 mL	1.0418 mL	2.0836 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.21 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.21 mM); Clear solution				

### BIOLOGICAL ACTIVITY

Description	NVS-PAK1-1 is a potent and selective allosteric PAK1 inhibitor with an IC <sub>50</sub> of 5 nM.
IC <sub>50</sub> & Target	IC <sub>50</sub> : 5 nM (PAK1) <sup>[1]</sup>
In Vitro	NVS-PAK1-1 demonstrates high selectivity for inhibition of PAK1 over other PAK isoforms and the kinome in general. NVS-PAK1-1 has a biochemical PAK1 K <sub>d</sub> of 7 nM and a PAK2 K <sub>d</sub> of 400 nM. NVS-PAK1-1 shows excellent activity in biochemical assays and an exceptional selectivity profile against other known kinases. NVS-PAK1-1 at 6-20 μM inhibits the phosphorylation of the downstream substrate MEK1 Ser289. Consistent with the observation, NVS-PAK1-1 inhibits proliferation of Su86.86 cell line only above a concentration of 2 μM. In contrast, by applying a mixture of NVS-PAK1-1 and PAK2 shRNA, inhibition of downstream signaling and cell proliferation at a significantly lower 0.21 μM concentration are

achieved<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

NVS-PAK1-1 shows a relatively poor stability in rat liver microsomes (RLM) and this would limit its application for in vivo studies ( $t_{1/2}$  in RLM 3.5 min)<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

#### Kinase Assay <sup>[1]</sup>

Inhibition of PAK1 kinase activity is measured using the Caliper assay. The assay is performed using 384-well microtiter plates. Compounds (NVS-PAK1-1) are tested as 8-point dose responses. The assays are prepared by addition of 50 nL of compound solution in 90% DMSO directly into the empty plate. Subsequently, 4.5  $\mu$ L of the enzyme solution is added to each well and the resulting solution is pre-incubated at 30°C for 60 min, followed by addition of 4.5  $\mu$ L of the peptide/ATP-solution. After 60 min incubation at 30°C, reactions are terminated by addition of 16  $\mu$ L per well of the stop solution. Plates with terminated kinase reactions are transferred to the Caliper LC3000 workstations for reading. Product formation is measured in a microfluidic mobility shift assay. IC<sub>50</sub> values are derived from percent inhibition values at different compound concentrations by non-linear regression analysis<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- bioRxiv. 2023 Jun 11.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Karpov AS, et al. Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor. ACS Med Chem Lett. 2015 May 22;6(7):776-81.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA